Related references
Note: Only part of the references are listed.The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation
Julia Schollbach et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2020)
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
Ernest Nadal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Michael Platten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas
M. Lisa Zhang et al.
MODERN PATHOLOGY (2019)
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
Biagio Ricciuti et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications
Martina Mandarano et al.
VIRCHOWS ARCHIV (2019)
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development
Mayanne M. T. Zhu et al.
CURRENT ONCOLOGY REPORTS (2019)
Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers
Avinoam Nevler et al.
CLINICAL CANCER RESEARCH (2019)
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1
Ashley Volaric et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Immunohistochemistry of Pulmonary Biomarkers A Perspective From Members of the Pulmonary Pathology Society
Erik Thunnissen et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma
Yuka Kozuma et al.
EUROPEAN JOURNAL OF CANCER (2018)
Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors
Anthony R. Guastellal et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors
Edwin Roger Parra et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Promoting epithelial-to-mesenchymal transition by D-kynurenine via activating aryl hydrocarbon receptor
Zhiqing Duan et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2018)
Expression of Indoleamine 2,3-Dioxygenase Induced by IFn-γ and TnF-α as Potential Biomarker of Prostate Cancer Progression
Irina Banzola et al.
FRONTIERS IN IMMUNOLOGY (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lipopolysaccharide shock reveals the immune function of indoleamine 2,3-dioxygenase 2 through the regulation of IL-6/stat3 signalling
Yasuko Yamamoto et al.
SCIENTIFIC REPORTS (2018)
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
Xingxiang Pu et al.
BMC CANCER (2018)
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Kurt A. Schalper et al.
CLINICAL CANCER RESEARCH (2017)
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Lieve Brochez et al.
EUROPEAN JOURNAL OF CANCER (2017)
P53 prevent tumor invasion and metastasis by down-regulating IDO in lung cancer
Dongfang Tang et al.
ONCOTARGET (2017)
The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO
Giada Mondanelli et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Investigation of the Tissue Distribution and Physiological Roles of Indoleamine 2,3-Dioxygenase-2
Felicita F. Jusof et al.
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2017)
Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas
Brandon R. Driver et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona Hendry et al.
ADVANCES IN ANATOMIC PATHOLOGY (2017)
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology
Cesare Gridelli et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
M-S. Tsao et al.
ANNALS OF ONCOLOGY (2017)
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2016)
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer
Elisabeth Brambilla et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism
Lauren M. F. Merlo et al.
JOURNAL OF IMMUNOLOGY (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
Jin Won Kim et al.
GASTRIC CANCER (2016)
A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
Nicholas C. D'Amato et al.
CANCER RESEARCH (2015)
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
A. Wang et al.
EJSO (2015)
Low efficiency IDO2 enzymes are conserved in lower vertebrates, whereas higher efficiency IDO1 enzymes are dispensable
Hajime J. Yuasa et al.
FEBS JOURNAL (2015)
Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
Michael Platten et al.
FRONTIERS IN IMMUNOLOGY (2015)
Tryptophan-degrading enzymes in tumoral immune resistance
Nicolas van Baren et al.
FRONTIERS IN IMMUNOLOGY (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1
Georgios Pantouris et al.
AMINO ACIDS (2014)
IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation
Richard Metz et al.
INTERNATIONAL IMMUNOLOGY (2014)
IDO2 in immunomodulation and autoimmune disease
George C. Prendergast et al.
FRONTIERS IN IMMUNOLOGY (2014)
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression
Jing-Yi Chen et al.
BREAST CANCER RESEARCH (2014)
Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
Young-Kwan Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2014)
Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease
Amos A. Fatokun et al.
AMINO ACIDS (2013)
Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
L. Ferdinande et al.
BRITISH JOURNAL OF CANCER (2012)
Status of cellular immunity lacks prognostic significance in vulvar squamous carcinoma
R. A. de Jong et al.
GYNECOLOGIC ONCOLOGY (2012)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism
Stefan Loeb et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials
Hajime J. Yuasa et al.
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY (2009)
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway
Helen J. Ball et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target
Agnieszka K. Witkiewicz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
Richard Metz et al.
CANCER RESEARCH (2007)
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice
Helen J. Ball et al.
GENE (2007)
Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma
K Hiraoka et al.
BRITISH JOURNAL OF CANCER (2006)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Share Paper
